Primary Navigation for the CDC Website
CDC en Español
Vaccine Safety
divider
E-Mail Icon E-mail this page
Printer Friendly Icon Printer-friendly version
divider
 Vaccine Safety Basics
bullet Information for Parents
bullet Why It's Important to Monitor Vaccine Safety
bullet How Vaccines Are Tested and Monitored
bullet Common Questions
bullet Vaccine Safety Concerns
bullet History of Vaccine Safety

 Public Health Activities
bullet Vaccine Adverse Event Reporting System (VAERS)
bullet Vaccine Safety Datalink (VSD) Project
bullet Clinical Immunization Safety Assessment (CISA) Network
bullet Brighton Collaboration
bullet Vaccine Technology
bullet Emergency Preparedness
bullet Publications
bullet 2008
bullet 2007
bullet 2006
bullet Scientific Agenda

2007 Scientific Articles

Beigel J, Kohl KS, Brinley F, Graham PL, Khuri-Bulos N, LaRussa PS, Nell P, Norton S, Stoltman G, Tebaa A, Warschaw K; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Generalized Vaccinia. Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5745–5753.

Beigel J, Kohl KS, Khuri-Bulos N, Bravo L, Nell P, Marcy SM, Warschaw K, Ong-Lim A, Poerschke G, Weston W, Lindstrom JA, Stoltman G, Maurer T; Brighton Collaboration Rash Working Group. Rash including mucosal involvement: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5697–5706.

Buettcher M, Baer G, Bonhoeffer J, Schaad UB, Heininger U. Three-year surveillance of intussusception in children in Switzerland. Pediatrics 2007;120(3):473–480.

Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, de Menezes Martins R, Vermeer-de Bondt P; Brighton Collaboration HHE Working Group. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2007;25(31):5875–5881.

Centers for Disease Control and Prevention (CDC). Postmarketing monitoring of intussusception after RotaTeq vaccination—United States, February 1, 2006–February 15, 2007. MMWR 2007;56(10):218–222.

DeStefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis [letter]. Pharmacoepidemiology and Drug Safety 2007;16(6):705–707.

Graham PL, LaRussa PS, Kohl KS; Brighton Collaboration Vaccinia Virus Adverse Event Working Group for Robust Take. Robust take following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5763–5770.

Haber MJ, Shay DK, Davis XM, Patel R, Jin X, Weintraub E, Orenstein E, Thompson WW. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerging Infectious Diseases 2007;13(4):581–589.

Halperin S, Kohl KS, Gidudu J, Ball L, Hammer SJ, Heath P, Hennig R, Labadie J, Rothstein E, Schuind A, Varricchio F, Walop W; Brighton Collaboration Local Reaction Working Group for Cellulitis at Injection Site. Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5803–5820.

Hirichsen V, Kruskal B, O'Brien MA, Lieu TA, Platt R; for the Vaccine Safety Datalink Team. Using electronic medical records to enhance detection and reporting of vaccine adverse events. Journal of the American Medical Informatics Association 2007;14(6):731–735.

Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, Baggs J, Carlone GM. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25(20):4029–4037.

Jackson ML, Nelson JC, Chen RT, Davis RL, Jackson LA; for the Vaccine Safety Datalink investigators. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiology and Drug Safety 2007;16(7):790–796.

Jones JF, Kohl KS, Ahmadipour N, Bleijenberg G, Buchwald D, Evengard B, Jason LA, Klimas NG, Lloyd A, McCleary K, Oleske JM, White PD; Brighton Collaboration Fatigue Working Group. Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5685–5696.

Jorch G, Tapiainen T, Bonhoeffer J, Fischer TK, Heininger U, Hoet B, Kohl KS, Lewis EM, Meyer C, Nelson T, Sandbu S, Schlaud M, Schwartz A, Varricchio F, Wise RP; Brighton Collaboration Unexplained Sudden Death Working Group. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5707–5716.

Klein NP, Fireman B, Enright A, Ray P, Black S, Dekker CL; Clinical Immunization Safety Assessment Network. A role for genetics in the immune response to the varicella vaccine. Pediatric Infectious Disease Journal 2007;26(4):300–305.

Kohl KS, Ball L, Gidudu J, Hammer SJ, Halperin S, Heath P, Hennig R, Labadie J, Rothstein E, Schuind A, Varricchio F, Walop W; Brighton Collaboration Local Reactions Working Group for Abscess at Injection Site. Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5821–5838.

Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, Drammeh B, Duclos P, Heijbel H, Heininger U, Hummelman E, Jefferson T, Keller-Stanislawski B, Loupi E, Marcy SM. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 2007;25(31):5671–5674.

Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Hennig R, Rothstein E, Schuind A, Varricchio F; Brighton Collaboration Local Reactions Working Group for Induration at or near Injection Site. Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5839–5857.

Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Varricchio F, Rothstein E, Schuind A, Hennig R; Brighton Collaboration Local Reaction Working Group for Swelling at or near Injection Site. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007;25(31):5858–5874.

Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R; for the Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Medical Care 2007;45(10 Supl 2):S89–95.

Miller ER, Iskander J, Pickering S, Varricchio F. How can you promote vaccine safety? Nursing 2007;37(4):58–63.

Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25(27):5086–5096.

Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, Black S, Shay DK; Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007;25(5):846–855.

Mullooly JP, Schuler R, Barrett M, Maher JE. Vaccines, antibiotics, and atopy. Pharmacoepidemiology and Drug Safety 2007;16(3):275–288.

Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, Martin B, McMahon A, Norton SA, Trolin I; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Progressive Vaccinia. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5735–5744.

Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, Martin B, Trolin I, Norton SA, Neff JM; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Eczema Vaccinatum. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5725–5734.

Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5675–5684.

Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, Gidudu J, Katikaneni L, Khuri-Bulos N, Oleske J, Tapiainen T, Wiznitzer M; Brighton Collaboration Encephalitis Working Group. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5771–5792.

Tapiainen T, Prevots R, Izurieta HS, Abramson J, Bilynsky R, Bonhoeffer J, Bonnet MC, Center K, Galama J, Gillard P, Griot M, Hartmann K, Heininger U, Hudson M, Koller A, Khetsuriani N, Khuri-Bulos N, Marcy SM, Matulionyte R, Schöndorf I, Sejvar J, Steele R; Brighton Collaboration Aseptic Meningitis Working Group. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007;25(31):5793–5802.

Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F; Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. New England Journal of Medicine 2007;357(13):1281–1292.

Wenger P, Oleske JM, Kohl KS, Fisher MC, Brien JH, Graham PL, LaRussa PS, Lipton S, Tierney B; Brighton Collaboration Vaccinia Virus Adverse Event Working Group for Inadvertent Inoculation. Inadvertent inoculation as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5754–5762.

Wise RP, Bonhoeffer J, Beeler J, Donato H, Downie P, Matthews D, Pool V, Riise-Bergsaker M, Tapiainen T, Varricchio F; Brighton Collaboration Thrombocytopenia Working Group. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5717–5724.

Wood R, Setse R, Halsey NA; Clinical Immunization Safety Assessment Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. Journal of Allergy and Clinical Immunology 2007;120(2):478–481.

Yu O, Bohlke K, Hanson CA, Delaney K, Rees TG, Zavitkovsky A, Ray P, Mullooly J, Black SB, Benson P, Thompson WW, Davis RL, Jackson LA. Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. Pharmacoepidemiology and Drug Safety 2007;16(7):736–745.

Page last reviewed: March 13, 2008 (archived document)
Page last updated: March 13, 2008
Content source: Immunization Safety Office, Office of the Chief Science Officer

  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
Safer, Healthier People

Centers for Disease Control and Prevention
1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
Public Inquiries: 1-800-CDC-INFO (232-4636); 1-888-232-6348 (TTY)
USA.govDHHS Department of Health
and Human Services